BACKGROUND: Methylation of tumor suppression genes (TSGs) is common in myeloid malignancies. However, application of this as a molecular marker for risk stratification in patients with AML is limited. DESIGN AND METHODS: To elucidate the impact of patterns of TSG methylation on outcome in cytogenetically normal patients, 106 samples from patients with having normal cytogenetic AML were evaluated for methylation of 12 genes by MSP. For sake of comparison, samples from patients with AML and abnormal cytogenetics (n = 63) were also evaluated. RESULTS: Methylation frequencies in the whole group (n = 169) were similar to previous reports for CDH1 (31%), ER (31%), FHIT (9%), p15 (INK4b) (44%), p73 (25%), and SOCS1 (75%). Methylation of CTNNA1 was observed in 10%, CEBP-α in16%, CEBP-δ in 2%, MLH1 in 24%, MGMT in 11% and DAPK in 2% of AML samples. We find that DNA methylation was more prevalent in patients with normal compared to karyotypically abnormal AML for most genes; CEBPα (20% vs 9%), CTNNA1 (14% vs 4%), and ER (41% vs 19%) (p < 0.05 for all comparisons). In contrast, p73 was more frequently methylated in patients with karyotypic abnormalities (17% vs 38%; p < 0.05), perhaps due to specific silencing of the pro-apoptotic promoter shifting p73 gene expression to the anti-apoptotic transcript. In AML patients with normal cytogenetics, TSG methylation was not associated with event free or overall survival in a multivariate analysis. CONCLUSIONS: In patients with AML, TSG methylation is more frequent in patients with normal karyotype than those with karyotypic abnormalities but does not confer independent prognostic information for patients with normal cytogenetics.
BACKGROUND: Methylation of tumor suppression genes (TSGs) is common in myeloid malignancies. However, application of this as a molecular marker for risk stratification in patients with AML is limited. DESIGN AND METHODS: To elucidate the impact of patterns of TSG methylation on outcome in cytogenetically normal patients, 106 samples from patients with having normal cytogenetic AML were evaluated for methylation of 12 genes by MSP. For sake of comparison, samples from patients with AML and abnormal cytogenetics (n = 63) were also evaluated. RESULTS: Methylation frequencies in the whole group (n = 169) were similar to previous reports for CDH1 (31%), ER (31%), FHIT (9%), p15 (INK4b) (44%), p73 (25%), and SOCS1 (75%). Methylation of CTNNA1 was observed in 10%, CEBP-α in16%, CEBP-δ in 2%, MLH1 in 24%, MGMT in 11% and DAPK in 2% of AML samples. We find that DNA methylation was more prevalent in patients with normal compared to karyotypically abnormal AML for most genes; CEBPα (20% vs 9%), CTNNA1 (14% vs 4%), and ER (41% vs 19%) (p < 0.05 for all comparisons). In contrast, p73 was more frequently methylated in patients with karyotypic abnormalities (17% vs 38%; p < 0.05), perhaps due to specific silencing of the pro-apoptotic promoter shifting p73 gene expression to the anti-apoptotic transcript. In AMLpatients with normal cytogenetics, TSG methylation was not associated with event free or overall survival in a multivariate analysis. CONCLUSIONS: In patients with AML, TSG methylation is more frequent in patients with normal karyotype than those with karyotypic abnormalities but does not confer independent prognostic information for patients with normal cytogenetics.
Authors: C A Linker; C A Ries; L E Damon; P Sayre; W Navarro; H S Rugo; A Rubin; D Case; P Crilley; D Topolsky; I Brodsky; K Zamkoff; J L Wolfe Journal: Biol Blood Marrow Transplant Date: 2000 Impact factor: 5.742
Authors: T Pabst; B U Mueller; N Harakawa; C Schoch; T Haferlach; G Behre; W Hiddemann; D E Zhang; D G Tenen Journal: Nat Med Date: 2001-04 Impact factor: 53.440
Authors: Javier Bolaños-Meade; Judith E Karp; Chuanfa Guo; Clarence B Sarkodee-Adoo; Aaron P Rapoport; Michael L Tidwell; Laxmi N Buddharaju; T Timothy Chen Journal: Leuk Res Date: 2003-04 Impact factor: 3.156
Authors: Shichun Zheng; Xiaomei Ma; Luoping Zhang; Laura Gunn; Martyn T Smith; Joseph L Wiemels; Kenneth Leung; Patricia A Buffler; John K Wiencke Journal: Cancer Res Date: 2004-03-15 Impact factor: 12.701
Authors: Xiaoyu Qu; Jerry Davison; Liping Du; Barry Storer; Derek L Stirewalt; Shelly Heimfeld; Elihu Estey; Frederick R Appelbaum; Min Fang Journal: Epigenetics Date: 2015 Impact factor: 4.528
Authors: Jeffery M Klco; David H Spencer; Tamara L Lamprecht; Shawn M Sarkaria; Todd Wylie; Vincent Magrini; Jasreet Hundal; Jason Walker; Nobish Varghese; Petra Erdmann-Gilmore; Cheryl F Lichti; Matthew R Meyer; R Reid Townsend; Richard K Wilson; Elaine R Mardis; Timothy J Ley Journal: Blood Date: 2013-01-07 Impact factor: 22.113
Authors: Ivana Gojo; Jan H Beumer; Keith W Pratz; Michael A McDevitt; Maria R Baer; Amanda L Blackford; B Douglas Smith; Steven D Gore; Hetty E Carraway; Margaret M Showel; Mark J Levis; Amy E Dezern; Douglas E Gladstone; Jiuping Jay Ji; Lihua Wang; Robert J Kinders; Marie Pouquet; Ismail Ali-Walbi; Michelle A Rudek; Weijie Poh; James G Herman; Larry M Karnitz; Scott H Kaufmann; Alice Chen; Judith E Karp Journal: Clin Cancer Res Date: 2016-08-08 Impact factor: 12.531